Innovent Biologics Inc (6IB:F) Annual Income Statement (EUR)
6IB:F Quarterly Financials (EUR)
Frequently Asked Questions About Innovent Biologics Inc (6IB:F) Stock
Innovent Biologics Inc's (6IB:F) last reported annual revenue was N/A.
Innovent Biologics Inc's (6IB:F) annual revenue growth rate based on the revenue reported in the past 5 years is : 265.79%
Innovent Biologics Inc's(6IB:F) is not profitable as of its last reported annual financials.
The net profit margin for Innovent Biologics Inc's(6IB:F) from its laster reported year is N/A
The return on equity (ROE) for Innovent Biologics Inc's(6IB:F) from its last reported annual financials is : -11.04%
The return on assets (ROA) for Innovent Biologics Inc's(6IB:F) from its last reported annual financials is : -4.18%
The return on invested capital (ROIC) for Innovent Biologics Inc's(6IB:F) from its last reported annual financials is : -6.09%
The Debt to Equity ratio for Innovent Biologics Inc's(6IB:F) from its last reported annual financials is : 18.57%
The dividend yield for Innovent Biologics Inc's(6IB:F) from its laster reported year is 0.00%
Innovent Biologics Inc's(6IB:F) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6IB:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
